Onclive » Lung Cancer
151 FOLLOWERS
The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non-small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.
Onclive » Lung Cancer
5d ago
TTFields plus supportive care improved time to intracranial progression in patients with brain metastases from non–small cell lung cancer ..read more
Onclive » Lung Cancer
5d ago
The European Commission has approved neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab, for high-risk, resectable NSCLC ..read more
Onclive » Lung Cancer
5d ago
Adagrasib improved progression-free survival and objective response rates vs docetaxel in pretreated KRAS G12C–mutant non–small cell lung cancer ..read more
Onclive » Lung Cancer
5d ago
Data from the phase 2 KICKSTART trial of tomivosertib plus pembrolizumab do not support the combination's use in patients with non–small cell lung cancer ..read more
Onclive » Lung Cancer
2w ago
Becotarug plus osimertinib elicited responses with manageable safety in patients with non–small cell lung cancer and EGFR exon 12 insertion mutations ..read more
Onclive » Lung Cancer
2w ago
Amivantamab plus chemotherapy extended the time to treatment discontinuation and subsequent therapy in EGFR exon 20 insertion–mutated NSCLC ..read more
Onclive » Lung Cancer
2w ago
Pembrolizumab plus olaparib as first-line maintenance therapy did not improve survival in patients with metastatic nonsquamous non–small cell lung cancer ..read more
Onclive » Lung Cancer
2w ago
Durvalumab/chemoradiation did not significantly improve survival vs chemoradiation alone in patients with unresectable non–small cell lung cancer ..read more
Onclive » Lung Cancer
2w ago
Anlotinib plus etoposide, carboplatin, and placebo improved PFS vs etoposide plus carboplatin and 2 placebos in first-line ES-SCLC ..read more
Onclive » Lung Cancer
2w ago
Osimertinib plus chemotherapy confers superior post-progression survival outcomes vs osimertinib alone in patients with EGFR-mutated NSCLC ..read more